GlassScriptPhysician profile
Angel Liu
NPI 1619691599
$2,521.37
in general payments reported to CMS, 2019-2025
25 companies · $2,365 in 2025
The $2,365 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $157 · 2025: $2,365.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,649 · Long Term Medical Supply Or Device Loan: $798 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,648.78 |
| Long Term Medical Supply Or Device Loan | $797.60 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,000.87 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $244.39 | 2025 | Calquence, Enhertu, Lynparza |
| Gilead Sciences, INC. | $216.31 | 2025 | Trodelvy |
| Janssen Biotech, INC. | $164.00 | 2025 | Rybrevant, Talvey, Tecvayli |
| Genentech USA, INC. | $90.73 | 2025 | Itovebi, Columvi, Polivy |
| Eisai INC. | $87.53 | 2024 | |
| Abbvie INC. | $78.65 | 2025 | |
| Seagen INC. | $74.99 | 2025 | |
| Merck Sharp & Dohme LLC | $67.75 | 2024-2025 | Keytruda, Lynparza |
| Beone Medicines USA, INC. | $45.44 | 2025 | Brukinsa, Tevimbra |
| Incyte Corporation | $44.30 | 2025 | Monjuvi, Pemazyre, Zynyz |
| Sobi, INC | $40.44 | 2025 | |
| Pfizer INC. | $36.47 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $36.00 | 2025 | Libtayo |
| Syndax Pharmaceuticals, INC. | $33.05 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genmab U.S., INC. | $31.67 | 2025 | Epkinly |
| Exelixis INC. | $30.33 | 2025 | Cabometyx |
| Lilly USA, LLC | $29.06 | 2025 | Jaypirca, Verzenio |
| Iovance Biotherapeutics, INC. | $28.68 | 2025 | Amtagvi |
| Pharmaessentia USA Corporation | $28.26 | 2025 | Besremi |
| Astellas Pharma US INC | $27.72 | 2025 | Vyloy |
| Bayer Healthcare Pharmaceuticals INC. | $25.06 | 2025 | |
| Agios Pharmaceuticals, INC. | $21.95 | 2024 | Pyrukynd |
| Corcept Therapeutics | $20.48 | 2025 | Korlym |
| Alnylam Pharmaceuticals INC. | $17.24 | 2025 | Givlaari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angel Liu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.